Compare Huntington Ingalls Industries Inc (HII) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Smith & Nephew plc — how do they compare? Huntington Ingalls Industries Inc trades at $265.67 (market cap $10.44B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Huntington Ingalls Industries Inc and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Smith & Nephew plc for 121 Days on average.
| HII | SNN | |
|---|---|---|
Market Cap | $10.44B | $11.10B |
Volume | 440,462 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $453.73 | $37.17 |
52-Week Low | $257.05 | $26.42 |
Typical Hold Time | 28 Days | 121 Days |
Enterprise Value | $13.37B | $14.13B |
Dividend Yield | 2.08% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $260.67, down 1.17% with bearish technical signals but strong fundamentals. The company shows consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders provide substantial revenue visibility. Valuation metrics appear reasonable with P/E of 15.78 and P/S of 0.79, while profitability metrics show ROE of 12.97% and net margin of 5.01%.
The investment case balances strong defense contracting fundamentals against technical weakness. Analyst consensus targets $363.67 (39% upside) with 40.7% buy ratings, though technical indicators show bearish momentum. Key risks include execution on large contracts and defense budget uncertainties, while catalysts include continued contract wins and autonomous technology expansion.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
